rs4986791, TLR4

N. diseases: 182
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Malignant Neoplasms
CUI: C0006826
Disease: Malignant Neoplasms
0.060 GeneticVariation BEFREE Our result indicated that two Single Nucleotide Polymorphisms (SNP) in TLR4 were associated with decreased cancer risk for rs4986791</span>: OR = 0.764, 95% CI: 0.652-0.894, <i>P =</i> 0.001 in allele model; OR = 0.769, 95%CI: 0.650-0.909, <i>P =</i> 0.002 in recessive model; OR = 0.505, 95% CI: 0.352-0.726, <i>P =</i> 0.000 in dominant model; for 11536889: OR = 0.927, 95% CI: 0.872-0.984, <i>P =</i> 0.013 in allele model; OR = 0.926, 95% CI: 0.862-0.944,<i>P =</i> 0.034 in recessive model. 29246004 2017
Malignant Neoplasms
CUI: C0006826
Disease: Malignant Neoplasms
0.060 GeneticVariation BEFREE Many epidemiological studies have shown the association between certain genetic variations in the Toll-like receptor 4 (TLR4) gene (for example, rs4986790 and rs4986791) and cancer risk. 26782430 2015
Malignant Neoplasms
CUI: C0006826
Disease: Malignant Neoplasms
0.060 GeneticVariation BEFREE Our meta-analysis identified that two SNPs (rs4986790 and rs4986791) in TLR4 were associated with increased cancer risk (for rs4986790: OR=1.24, 95% CI=1.01-1.52 in dominant model; OR=1.24, 95% CI=1.02-1.52 in overdominant model; for rs4986791: OR=1.81, 95% CI=1.18-2.77 in allele comparison; OR=1.79, 95% CI=1.15-2.80 in dominant model; OR=1.70, 95% CI=1.09-2.67 in overdominant model) and one SNP (rs1927911) in TLR4 was associated with decreased cancer risk (for rs1927911: OR=0.63, 95% CI=0.41-0.99 in allele comparison; OR=0.57, 95% CI=0.35-0.95 in dominant model; OR=0.67, 95% CI=0.46-0.97 in codominant model). 23084080 2013
Malignant Neoplasms
CUI: C0006826
Disease: Malignant Neoplasms
0.060 GeneticVariation BEFREE However, the association between rs4986791 and cancer risk was significant in both South Asians and East Asians, but not in Caucasians. 24376595 2013
Malignant Neoplasms
CUI: C0006826
Disease: Malignant Neoplasms
0.060 GeneticVariation BEFREE Thr399Ile polymorphism was significantly associated with an elevated cancer risk in overall analysis (T allele versus C allele, OR=1.72, 95% CI: 1.27-2.33; TC versus CC, OR=1.63, 95% CI: 1.18-2.26; TT+TC versus CC, OR=1.70, 95% CI: 1.24-2.34) and especially in gastrointestinal subgroup (T allele versus C allele, OR=2.01, 95% CI: 1.40-2.89; TC versus CC, OR=1.86, 95% CI: 1.26-2.74; TT+TC versus CC, OR=1.97, 95% CI: 1.35-2.88). 22441122 2012
Malignant Neoplasms
CUI: C0006826
Disease: Malignant Neoplasms
0.060 GeneticVariation BEFREE In a prospective cohort study, we examined 62 patients undergoing major surgical cancer therapy for Toll-like receptor 4 (TLR4) gene polymorphisms (Asp299Gly and Thr399Ile) and their influence on cytokine levels pre- and postoperatively, as well as cytokine levels after whole blood lipopolysaccharide (LPS) stimulation. 16525349 2006